title: Bevacizumab is active in malignant effusion.
authors.forename: O
authors.initials: O
authors.lastname: Pichelmayer
authors.forename: B
authors.initials: B
authors.lastname: Gruenberger
authors.forename: C
authors.initials: C
authors.lastname: Zielinski
authors.forename: M
authors.initials: M
authors.lastname: Raderer
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D016066:Pleural Effusion, Malignant / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab